<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364286</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0497</org_study_id>
    <nct_id>NCT00364286</nct_id>
  </id_info>
  <brief_title>Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)</brief_title>
  <official_title>Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if dasatinib can help to control Chronic
      Lymphocytic Leukemia (CLL). The safety of the drug will also be studied.

      Optional Procedures: You will be asked to have additional blood samples drawn. These samples
      will be used to see how the disease is responding to the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dasatinib is designed to interfere with a type of protein that appears to be important for
      the survival of CLL cells.

      If you are found to be eligible to take part in this study, you will take dasatinib by mouth
      twice a day. You will be instructed to take dasatinib in the morning and in the evening.

      You will have an electrocardiogram (ECG—a test of the electrical activity of your heart) and
      a physical exam once every 3 months while on study. Blood (about 2-3 teaspoons) will be drawn
      for routine tests once a week for 1 month and then once a month for the rest of your
      treatment on this study. A bone marrow biopsy and aspiration will be performed, as needed, to
      check the status of the disease. To collect a bone marrow aspirate and biopsy, an area of the
      hip or chest bone is numbed with anesthetic, and a small amount of bone marrow and bone is
      withdrawn through a large needle.

      Dasatinib will be given for as long as you are responding. You will be taken off study if the
      disease gets worse or intolerable side effects occur.

      This is an investigational study. Dasatinib is not FDA-approved for CLL, and it has been
      authorized for use in research only. Up to 25 patients will take part in this multicenter
      study. Up to 25 will be enrolled at M. D. Anderson.

      Optional Procedures: If you agree, blood samples (about 2 tablespoons each time) will be
      collected before therapy starts, at 3-4 hours after the first dose, and at 3 months on
      therapy. These blood draws will be done when other routine tests are done. No additional
      needle sticks will be needed. The blood will be used to see how the disease is responding to
      the drug.

      You do not have to agree to take part in the optional procedures in order to receive
      treatment on this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Objective Response</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Number of participants with an Objective Response defined as Complete Response (CR) or Partial Response (PR). Responses evaluated every 3 months +/- 1 week by each component and overall by National Cancer Institute Working Group (NCIWG) criteria where Response judged, Nodes for CR: None; PR: &gt; 50% decrease; Liver/Spleen CR: Not palpable; PR: &gt; 50% decrease; Symptoms for CR: None; PR: Not applicable (N/A); polymorphonuclear leukocyte (PMN) for CR: &gt;1,500/μl, PR: &gt; 1,500/μl or &gt;50% improvement from baseline; Platelets for CR: &gt;100,000/μl, PR: &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused) for CR: &gt;11,0 g/dl; PR: &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes for CR: &lt;4,000/μl and PR: &gt;50% decrease; Bone Marrow aspirate for CR: &lt;30% lymphocytes, N/A for PR; Bone Biopsy for CR: No lymphocyte infiltrate; PR: &lt; 30% lymphocytes with residual disease on biopsy for nodular PR.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib 50mg Orally twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib (BMS-354825)</intervention_name>
    <description>50mg Orally twice daily</description>
    <arm_group_label>Dasatinib</arm_group_label>
    <other_name>Dasatinib</other_name>
    <other_name>SPRYCEL ™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of CLL, Small lymphocytic lymphoma (SLL), or -cell prolymphocytic leukemia
             (T-PLL).

          2. Previously treated with chemotherapy or monoclonal antibodies.

          3. All patients with Rai stage III-IV are eligible. - OR - Patients with Rai stage 0-II
             who meet one or more indication for treatment as defined by the NCI-sponsored Working
             Group are eligible:Massive or progressive splenomegaly; Massive lymph nodes, nodal
             clusters, or progressive lymphadenopathy; Grade 2 or 3 fatigue, fever &gt;/= 100.5
             degrees F, night sweats for &gt; 2 weeks w/o documented infection, presence of weight
             loss &gt;/= 10% over the preceding 6 months; Progressive lymphocytosis with increase in
             lymphocyte count of &gt;/= 50% over a 2-month period or an anticipated doubling time of &lt;
             6 months.

          4. Serum bilirubin less than 2mg/dL, serum creatinine less than 2mg/dL unless abnormality
             is considered due to CLL by investigator.

          5. The Eastern Cooperative Oncology Group (ECOG) Performance Status &lt; 3.

          6. Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study, in keeping with the policies of the hospital.

          7. Sexually active women of childbearing potential must use birth control during study in
             manner that risk of failure is minimized. Prior to study enrollment women of
             childbearing potential must be advised of importance of avoiding pregnancy during
             trial and potential risk factors for unintentional pregnancy. MUST have negative
             pregnancy test. If pregnancy test is positive patient must not receive investigational
             product and must not be enrolled in study. Men enrolled on study should understand
             risks to sexual partner of childbearing potential and practice effective birth
             control.

          8. Inclusion of women and minorities: As per NIH policy, women and members of minorities
             will be included in this protocol as they are referred in the relevant populations.
             There are no exclusions of women or minorities based on the study objectives.

          9. New York Heart Association (NYHA) Class &lt; 3

         10. Patients must sign informed consent.

        Exclusion Criteria:

          1. Pregnant or breast-feeding women are excluded.

          2. Patients may not receive concurrent chemotherapy, radiotherapy, or immunotherapy.
             Localized radiotherapy to an area not compromising bone marrow function does not
             apply, nor do hematopoietic growth factors such as erythropoietin, G-CSF, GM-CSF etc.

          3. Patients must not have untreated or uncontrolled life-threatening infection.

          4. Uncontrolled angina within 3 months; diagnosed or suspected congenital long QT
             syndrome; any history of clinically significant ventricular arrhythmias; prolonged QTc
             interval (&gt; 450 msec); uncontrolled hypertension; significant bleeding disorder
             unrelated to cancer; patients currently taking drugs that are generally accepted to
             have a risk of causing Torsades de Pointes.

          5. Medications that inhibit platelet function (i.e., aspirin, dipyridamole, epoprostenol,
             eptifibatide, clopidogrel, cilostazol, abciximab, ticlopidine, and any non-steroidal
             anti-inflammatory drug) or Anticoagulants (warfarin, heparin/low molecular weight
             heparin [e.g., danaparoid, dalteparin, tinzaparin, enoxaparin]).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan O'Brien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>UT M.D. Anderson's Website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <results_first_submitted>June 12, 2013</results_first_submitted>
  <results_first_submitted_qc>June 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2013</results_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Prolymphocytic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Dasatinib</keyword>
  <keyword>BMS-354825</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 8/14/2006 through 11/28/2012. All participants recruited at The University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Dasatinib</title>
          <description>Dasatinib 50mg Orally twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dasatinib</title>
          <description>Dasatinib 50mg Orally twice daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="42" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Objective Response</title>
        <description>Number of participants with an Objective Response defined as Complete Response (CR) or Partial Response (PR). Responses evaluated every 3 months +/- 1 week by each component and overall by National Cancer Institute Working Group (NCIWG) criteria where Response judged, Nodes for CR: None; PR: &gt; 50% decrease; Liver/Spleen CR: Not palpable; PR: &gt; 50% decrease; Symptoms for CR: None; PR: Not applicable (N/A); polymorphonuclear leukocyte (PMN) for CR: &gt;1,500/μl, PR: &gt; 1,500/μl or &gt;50% improvement from baseline; Platelets for CR: &gt;100,000/μl, PR: &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused) for CR: &gt;11,0 g/dl; PR: &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes for CR: &lt;4,000/μl and PR: &gt;50% decrease; Bone Marrow aspirate for CR: &lt;30% lymphocytes, N/A for PR; Bone Biopsy for CR: No lymphocyte infiltrate; PR: &lt; 30% lymphocytes with residual disease on biopsy for nodular PR.</description>
        <time_frame>up to 3 months</time_frame>
        <population>Three participants were not evaluable for response due to early discontinuation of treatment (0-3 days).</population>
        <group_list>
          <group group_id="O1">
            <title>Dasatinib</title>
            <description>Dasatinib 50mg Orally twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Objective Response</title>
          <description>Number of participants with an Objective Response defined as Complete Response (CR) or Partial Response (PR). Responses evaluated every 3 months +/- 1 week by each component and overall by National Cancer Institute Working Group (NCIWG) criteria where Response judged, Nodes for CR: None; PR: &gt; 50% decrease; Liver/Spleen CR: Not palpable; PR: &gt; 50% decrease; Symptoms for CR: None; PR: Not applicable (N/A); polymorphonuclear leukocyte (PMN) for CR: &gt;1,500/μl, PR: &gt; 1,500/μl or &gt;50% improvement from baseline; Platelets for CR: &gt;100,000/μl, PR: &gt;100,000/μl or &gt; 50% improvement from baseline; Hemoglobin (untransfused) for CR: &gt;11,0 g/dl; PR: &gt;11.0 g/dl or &gt;50% improvement from baseline; Lymphocytes for CR: &lt;4,000/μl and PR: &gt;50% decrease; Bone Marrow aspirate for CR: &lt;30% lymphocytes, N/A for PR; Bone Biopsy for CR: No lymphocyte infiltrate; PR: &lt; 30% lymphocytes with residual disease on biopsy for nodular PR.</description>
          <population>Three participants were not evaluable for response due to early discontinuation of treatment (0-3 days).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response (CR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Objective Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 Years, 3 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dasatinib</title>
          <description>Dasatinib 50mg Orally twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Secondary Malignancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>flushing</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan O'Brien, MD/ Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-7543</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

